Search Results - "Foy, Susan"

PEG-Functionalized Magnetic Nanoparticles for Drug Delivery and Magnetic Resonance Imaging Applications by Yallapu, Murali Mohan, Foy, Susan P, Jain, Tapan K, Labhasetwar, Vinod

“…Purpose Polyethylene glycol (PEG) functionalized magnetic nanoparticles (MNPs) were tested as a drug carrier system, as a magnetic resonance imaging (MRI)…”
Get full text

Oh the irony: Iron as a cancer cause or cure? by Foy, Susan P, Labhasetwar, Vinod

“…Abstract Iron-oxide nanoparticles facilitate cancer diagnosis through enhanced contrast, selectively enhance tumor cell death with magnetic hyperthermia, and…”
Get full text

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy by Puig-Saus, Cristina, Sennino, Barbara, Peng, Songming, Wang, Clifford L., Pan, Zheng, Yuen, Benjamin, Purandare, Bhamini, An, Duo, Quach, Boi B., Nguyen, Diana, Xia, Huiming, Jilani, Sameeha, Shao, Kevin, McHugh, Claire, Greer, John, Peabody, Phillip, Nayak, Saparya, Hoover, Jonathan, Said, Sara, Jacoby, Kyle, Dalmas, Olivier, Foy, Susan P., Conroy, Andrew, Yi, Michael C., Shieh, Christine, Lu, William, Heeringa, Katharine, Ma, Yan, Chizari, Shahab, Pilling, Melissa J., Ting, Marc, Tunuguntla, Ramya, Sandoval, Salemiz, Moot, Robert, Hunter, Theresa, Zhao, Sidi, Saco, Justin D., Perez-Garcilazo, Ivan, Medina, Egmidio, Vega-Crespo, Agustin, Baselga-Carretero, Ignacio, Abril-Rodriguez, Gabriel, Cherry, Grace, Wong, Deborah J., Hundal, Jasreet, Chmielowski, Bartosz, Speiser, Daniel E., Bethune, Michael T., Bao, Xiaoyan R., Gros, Alena, Griffith, Obi L., Griffith, Malachi, Heath, James R., Franzusoff, Alex, Mandl, Stefanie J., Ribas, Antoni

“…Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells 1 – 14…”
Get full text

Optical Imaging and Magnetic Field Targeting of Magnetic Nanoparticles in Tumors by Foy, Susan P., Manthe, Rachel L., Foy, Steven T., Dimitrijevic, Sanja, Krishnamurthy, Nishanth, Labhasetwar, Vinod

“…To address efficacy issues of cancer diagnosis and chemotherapy, we have developed a magnetic nanoparticle (MNP) formulation with combined drug delivery and…”
Get full text

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice by Foy, Susan P, Sennino, Barbara, dela Cruz, Tracy, Cote, Joseph J, Gordon, Evan J, Kemp, Felicia, Xavier, Veronica, Franzusoff, Alex, Rountree, Ryan B, Mandl, Stefanie J

“…Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While…”
Get full text

Tumor Ablation and Nanotechnology by Manthe, Rachel L, Foy, Susan P, Krishnamurthy, Nishanth, Sharma, Blanka, Labhasetwar, Vinod

“…Next to surgical resection, tumor ablation is a commonly used intervention in the treatment of solid tumors. Tumor ablation methods include thermal therapies,…”
Get full text

Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice by Jain, Tapan K, Foy, Susan P, Erokwu, Bernadette, Dimitrijevic, Sanja, Flask, Christopher A, Labhasetwar, Vinod

“…Abstract We are investigating the magnetic resonance imaging characteristics of magnetic nanoparticles (MNPs) that consist of an iron-oxide magnetic core…”
Get full text

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells by Foy, Susan P., Mandl, Stefanie J., dela Cruz, Tracy, Cote, Joseph J., Gordon, Evan J., Trent, Erica, Delcayre, Alain, Breitmeyer, James, Franzusoff, Alex, Rountree, Ryan B.

“…The dramatic clinical benefit of immune checkpoint blockade for a fraction of cancer patients suggests the potential for further clinical benefit in a broader…”
Get full text

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy by Mandl, Stefanie J, Rountree, Ryan B, Dela Cruz, Tracy B, Foy, Susan P, Cote, Joseph J, Gordon, Evan J, Trent, Erica, Delcayre, Alain, Franzusoff, Alex

“…PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous…”
Get full text

The impact of third molar symptoms, pain, and swelling on oral health-related quality of life by Slade, Gary D., Foy, Susan P., Shugars, Daniel A., Phillips, Ceib, White, Raymond P.

“…This study was designed to assess the impact of “pain and swelling” associated with third molars on patients’ quality of life before surgery. The data for…”
Get full text

The impact of intravenous corticosteroids with third molar surgery in patients at high risk for delayed health-related quality of life and clinical recovery by Tiwana, Paul S., Foy, Susan P., Shugars, Daniel A., Marciani, Robert D., Conrad, Shawn M., Phillips, Ceib, White, Raymond P.

“…To compare recovery for clinical and health-related quality of life (HRQOL) outcomes after third molar surgery in patients predicted to be at risk for delayed…”
Get full text

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer by Foy, Susan P, Rountree, Ryan B, Cote, Joseph, dela Cruz, Tracy, Gordon, Evan, Trent, Erica, Franzusoff, Alex, Breitmeyer, James B, Mandl, Stefanie J

“…Combining poxvirus-based immunotherapies which "step on the gas" to activate tumor antigen-specific T cell immune responses with immune checkpoint inhibitors…”
Get full text

The impact of intravenous antibiotics on health-related quality of life outcomes and clinical recovery after third molar surgery by Foy, Susan P, Shugars, Daniel A, Phillips, Ceib, Marciani, Robert D, Conrad, Shawn M, White, Raymond P

“…Purpose: We sought to compare recovery for clinical and health-related quality of life (HRQOL) outcomes after third molar surgery in patients treated with or…”
Get full text

Non-viral precision T cell receptor replacement for personalized cell therapy by Foy, Susan P., Jacoby, Kyle, Bota, Daniela A., Hunter, Theresa, Pan, Zheng, Stawiski, Eric, Ma, Yan, Lu, William, Peng, Songming, Wang, Clifford L., Yuen, Benjamin, Dalmas, Olivier, Heeringa, Katharine, Sennino, Barbara, Conroy, Andy, Bethune, Michael T., Mende, Ines, White, William, Kukreja, Monica, Gunturu, Swetha, Humphrey, Emily, Hussaini, Adeel, An, Duo, Litterman, Adam J., Quach, Boi Bryant, Ng, Alphonsus H. C., Lu, Yue, Smith, Chad, Campbell, Katie M., Anaya, Daniel, Skrdlant, Lindsey, Huang, Eva Yi-Hsuan, Mendoza, Ventura, Mathur, Jyoti, Dengler, Luke, Purandare, Bhamini, Moot, Robert, Yi, Michael C., Funke, Roel, Sibley, Alison, Stallings-Schmitt, Todd, Oh, David Y., Chmielowski, Bartosz, Abedi, Mehrdad, Yuan, Yuan, Sosman, Jeffrey A., Lee, Sylvia M., Schoenfeld, Adam J., Baltimore, David, Heath, James R., Franzusoff, Alex, Ribas, Antoni, Rao, Arati V., Mandl, Stefanie J.

“…T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells 1 – 3 . Here we developed a clinical-grade approach based on…”
Get full text

Abstract 3125: TCR specificity prediction of circulating T cells and TILs in personalized adoptive neoTCR T cell therapy by Borrman, Tyler, Stawiski, Eric, Pan, Zheng, Smith, Chad, Foy, Susan, Mandl, Stefanie J.

“…Abstract Background: Adoptive T-cell therapies would benefit from accurate computational prediction of T cell receptor (TCR) specificity to its target antigen…”
Get full text

Abstract 4783: Highly efficient, non-viral precision genome engineering for the generation of personalized neoepitope-specific adoptive T cell therapies by Jacoby, Kyle, Moot, Robert, Lu, William, Nguyen, Diana, Sennino, Barbara, Conroy, Andrew, Purandare, Bhamini, Litterman, Adam J., Urbinati, Fabrizia, Foy, Susan P., Hunter, Theresa, Tai, Albert, Bethune, Michael T., Peng, Songming, Dalmas, Olivier, Franzusoff, Alex, Mandl, Stefanie J.

“…Abstract Methods used to engineer cells for adoptive cell therapies (ACT) utilizing receptors that are constant across many patients (CAR or shared Ag TCRs)…”
Get full text

Abstract 1433: NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen by Sennino, Barbara, Conroy, Andrew, Purandare, Bhamini, Litterman, Adam, Jacoby, Kyle, Moot, Robert, Lu, William, Nguyen, Diana, Urbinati, Fabrizia, Foy, Susan, Hunter, Theresa, Dalmas, Olivier, Bethune, Michael, Park, Tim, Peng, Songming, Franzusoff, Alex, Mandl, Stefanie

“…Abstract Clinical benefit observed with immuno-oncology trials often depends on the unleashing of a pre-existing intrinsic T cell immune response in each…”
Get full text

Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model by Powers, Janine, Palencia, Servando, Foy, Susan, Sennino, Barbara, Hidalgo, Toni Rose, Gemo, Abigael, Brennan, Thomas, Pierce, Kisten

“…Abstract Five Prime Therapeutics, Inc. has developed an FGFR2b-specific humanized monoclonal antibody, FPA144, to treat patients with cancer bearing…”
Get full text

Abstract 901: Monitoring of neoantigens and adoptively transferred personalized neoTCR T cell populations in the tumor and PBMCs of patients with solid tumors by Foy, Susan, Wang, Cliff, Yuen, Benjamin, Said, Sara, Quach, Boi, Hoover, Jonathan, Nayak, Saparya, Hunter, Theresa, Pan, Zheng, Smith, Chad, Borrman, Tyler, Stawiski, Eric, Ng, Alphonsus H. C., Lu, Yue, Heath, James, Mandl, Stefanie

“…Abstract Background: NeoTCR-P1 is a personalized autologous T cell therapy for treatment of patients with solid tumors. Neoantigen-specific T cell receptors…”
Get full text

Abstract LB-234: Poxvirus-based active immunotherapy synergizes with PD-1 plus LAG-3 immune checkpoint inhibition to enhance antitumor efficacy in preclinical models by Sennino, Barbara, Foy, Susan P., Rountree, Ryan B., dela Cruz, Tracy, Gordon, Evan J., Xavier, Veronica, Kemp, Felicia, Franzusoff, Alex, Breitmeyer, James, Mandl, Stefanie J.

“…Abstract Treatment with poxvirus-based active immunotherapies shows evidence of robust immune responses against a variety of tumor-associated antigens in…”
Get full text